Summary by Moomoo AI
SHANGHAI FUXING PHARMACEUTICALS (GROUP) CO., LTD. (“FUXING PHARMACEUTICALS”) ISSUED ITS FIRST QUARTER REPORT FOR 2024 ON 29 APRIL 2024. The report showed that Pustar Pharmaceuticals achieved sales revenue of approximately $101.57 billion in the quarter, down 6.56% year-on-year. Net profit attributable to shareholders of listed companies was approximately $6.10 billion, down by 38.22% year-on-year. Basic earnings per share were $0.23, down 37.84% from the same period last year. During the reporting period, the net cash flow generated by the operations of Fustar Pharmaceuticals was US$9.17 billion, an increase of 5.05% year-on-year. The Board of Directors of the Company and all Directors ensure that the content of the reports is truthful, accurate, complete and legally liable. FUSTAR PHARMACEUTICALS SAID THE DECLINE IN REVENUE WAS MAINLY...Show More